Improvements in cognitive performance switching from efavirenz‐ to dolutegravir‐based antiretroviral therapy in South African people with HIV: the CONNECT study

Cognitive improvements likely represent efavirenz neurotoxicity. Rates of low cognitive performance in people with HIV following ART switch are lower than previously reported in an African setting. CSF HIV RNA escape was uncommon and/or transient on both treatment regimens. These data provide reassurance regarding brain health in people with HIV on modern ART, although the effect of ageing with HIV requires further exploration.